Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major focal segmental glomerulosclerosis markets reached a value of US$ 332.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 578.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2024-2034.
The focal segmental glomerulosclerosis market has been comprehensively analyzed in IMARC's new report titled "Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Focal segmental glomerulosclerosis (FSGS) refers to a condition in which scar tissue forms on the glomeruli, the tiny part of the kidney responsible for removing waste from the blood. This results in damage to the kidney's filtration function and an abnormal loss of protein in the urine. The most common symptoms of the ailment include frothy urine, excess water retention, pitting edema, susceptibility to infection, fatty casts in the urine, etc. Individuals suffering from FSGS may also experience weight gain due to excess fluid building up in the body, high-fat levels in the blood, a poor appetite, fatigue, etc. The diagnosis typically involves a combination of laboratory investigations and imaging studies. A urine test helps in identifying the presence of proteinuria, while a blood test is performed to check for signs of kidney damage, such as elevated creatinine levels. Various imaging studies, including an ultrasound or CT scan, are utilized to visualize the kidneys and check for any abnormalities. Additionally, a renal biopsy, in which a small portion of the kidney is extracted using a special needle and examined under a microscope, is required to confirm the presence of FSGS among patients.
The rising prevalence of several associated risk factors, such as kidney infections, exposure to toxins, genetic mutations, underlying medical conditions like HIV and sickle cell disease, etc., is primarily driving the focal segmental glomerulosclerosis market. In addition to this, the widespread adoption of certain medications, including bisphosphonates, anabolic steroids, anthracyclines, calcineurin inhibitors, etc., that damage renal podocytes is also propelling the market growth. Furthermore, the inflating utilization of corticosteroids in the treatment of FSGS, which prevent the immune system from attacking the glomeruli and affecting renal function, is acting as another significant growth-inducing factor. Apart from this, the escalating application of plasmapheresis to reduce proteinuria and improve kidney function in patients is further creating a positive outlook for the market. Moreover, numerous key players are making extensive investments in R&D activities to launch innovative diagnostic techniques, such as next-generation sequencing technology, that provide higher specificity and sensitivity than conventional methods. This, in turn, is also bolstering the market growth. Additionally, the emerging popularity of anti-hypertensive therapy for treating the ailment since it can reduce the risk of further kidney damage and delay the need for more aggressive treatments, such as dialysis or kidney transplant, is expected to drive the focal segmental glomerulosclerosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the focal segmental glomerulosclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for focal segmental glomerulosclerosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the focal segmental glomerulosclerosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the focal segmental glomerulosclerosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the focal segmental glomerulosclerosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current focal segmental glomerulosclerosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the focal segmental glomerulosclerosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the focal segmental glomerulosclerosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the focal segmental glomerulosclerosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with focal segmental glomerulosclerosis across the seven major markets?
What is the size of the focal segmental glomerulosclerosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of focal segmental glomerulosclerosis?
What will be the growth rate of patients across the seven major markets?
Focal Segmental Glomerulosclerosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for focal segmental glomerulosclerosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the focal segmental glomerulosclerosis market?
What are the key regulatory events related to the focal segmental glomerulosclerosis market?
What is the structure of clinical trial landscape by status related to the focal segmental glomerulosclerosis market?
What is the structure of clinical trial landscape by phase related to the focal segmental glomerulosclerosis market?
What is the structure of clinical trial landscape by route of administration related to the focal segmental glomerulosclerosis market?
The focal segmental glomerulosclerosis market has been comprehensively analyzed in IMARC's new report titled "Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Focal segmental glomerulosclerosis (FSGS) refers to a condition in which scar tissue forms on the glomeruli, the tiny part of the kidney responsible for removing waste from the blood. This results in damage to the kidney's filtration function and an abnormal loss of protein in the urine. The most common symptoms of the ailment include frothy urine, excess water retention, pitting edema, susceptibility to infection, fatty casts in the urine, etc. Individuals suffering from FSGS may also experience weight gain due to excess fluid building up in the body, high-fat levels in the blood, a poor appetite, fatigue, etc. The diagnosis typically involves a combination of laboratory investigations and imaging studies. A urine test helps in identifying the presence of proteinuria, while a blood test is performed to check for signs of kidney damage, such as elevated creatinine levels. Various imaging studies, including an ultrasound or CT scan, are utilized to visualize the kidneys and check for any abnormalities. Additionally, a renal biopsy, in which a small portion of the kidney is extracted using a special needle and examined under a microscope, is required to confirm the presence of FSGS among patients.
The rising prevalence of several associated risk factors, such as kidney infections, exposure to toxins, genetic mutations, underlying medical conditions like HIV and sickle cell disease, etc., is primarily driving the focal segmental glomerulosclerosis market. In addition to this, the widespread adoption of certain medications, including bisphosphonates, anabolic steroids, anthracyclines, calcineurin inhibitors, etc., that damage renal podocytes is also propelling the market growth. Furthermore, the inflating utilization of corticosteroids in the treatment of FSGS, which prevent the immune system from attacking the glomeruli and affecting renal function, is acting as another significant growth-inducing factor. Apart from this, the escalating application of plasmapheresis to reduce proteinuria and improve kidney function in patients is further creating a positive outlook for the market. Moreover, numerous key players are making extensive investments in R&D activities to launch innovative diagnostic techniques, such as next-generation sequencing technology, that provide higher specificity and sensitivity than conventional methods. This, in turn, is also bolstering the market growth. Additionally, the emerging popularity of anti-hypertensive therapy for treating the ailment since it can reduce the risk of further kidney damage and delay the need for more aggressive treatments, such as dialysis or kidney transplant, is expected to drive the focal segmental glomerulosclerosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the focal segmental glomerulosclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for focal segmental glomerulosclerosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the focal segmental glomerulosclerosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the focal segmental glomerulosclerosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the focal segmental glomerulosclerosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current focal segmental glomerulosclerosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the focal segmental glomerulosclerosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the focal segmental glomerulosclerosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the focal segmental glomerulosclerosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of focal segmental glomerulosclerosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with focal segmental glomerulosclerosis across the seven major markets?
What is the size of the focal segmental glomerulosclerosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of focal segmental glomerulosclerosis?
What will be the growth rate of patients across the seven major markets?
Focal Segmental Glomerulosclerosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for focal segmental glomerulosclerosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the focal segmental glomerulosclerosis market?
What are the key regulatory events related to the focal segmental glomerulosclerosis market?
What is the structure of clinical trial landscape by status related to the focal segmental glomerulosclerosis market?
What is the structure of clinical trial landscape by phase related to the focal segmental glomerulosclerosis market?
What is the structure of clinical trial landscape by route of administration related to the focal segmental glomerulosclerosis market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - UNMET NEEDS
10 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - KEY ENDPOINTS OF TREATMENT
11 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - MARKETED PRODUCTS
11.1 List of Focal Segmental Glomerulosclerosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - PIPELINE DRUGS
12.1 List of Focal Segmental Glomerulosclerosis Pipeline Drugs Across the Top 7 Markets
12.1.1 PF 06730512 - Pfizer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RE-021 (Sparsentan) - Travere Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VX 147 - Vertex Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Atrasentan - Chinook Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 DMX-200 - Dimerix Bioscience
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FOCAL SEGMENTAL GLOMERULOSCLEROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FOCAL SEGMENTAL GLOMERULOSCLEROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Focal Segmental Glomerulosclerosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Focal Segmental Glomerulosclerosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Focal Segmental Glomerulosclerosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Focal Segmental Glomerulosclerosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Focal Segmental Glomerulosclerosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Focal Segmental Glomerulosclerosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Focal Segmental Glomerulosclerosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Focal Segmental Glomerulosclerosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
16 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - UNMET NEEDS
10 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - KEY ENDPOINTS OF TREATMENT
11 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - MARKETED PRODUCTS
11.1 List of Focal Segmental Glomerulosclerosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - PIPELINE DRUGS
12.1 List of Focal Segmental Glomerulosclerosis Pipeline Drugs Across the Top 7 Markets
12.1.1 PF 06730512 - Pfizer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RE-021 (Sparsentan) - Travere Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VX 147 - Vertex Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Atrasentan - Chinook Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 DMX-200 - Dimerix Bioscience
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FOCAL SEGMENTAL GLOMERULOSCLEROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FOCAL SEGMENTAL GLOMERULOSCLEROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Focal Segmental Glomerulosclerosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Focal Segmental Glomerulosclerosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Focal Segmental Glomerulosclerosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Focal Segmental Glomerulosclerosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Focal Segmental Glomerulosclerosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Focal Segmental Glomerulosclerosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Focal Segmental Glomerulosclerosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Focal Segmental Glomerulosclerosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Focal Segmental Glomerulosclerosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Focal Segmental Glomerulosclerosis - Access and Reimbursement Overview
16 FOCAL SEGMENTAL GLOMERULOSCLEROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
